What is the recommended dosing, administration schedule, contraindications (including G6PD deficiency), and monitoring parameters for rasburicase in patients receiving cytotoxic chemotherapy?

Rasburicase Dosing and Management

Rasburicase should be dosed at 0.10-0.2 mg/kg IV once daily (with expert practice favoring lower doses of 0.10-0.15 mg/kg or fixed doses of 3-6 mg in adults), administered over 30 minutes for 1-7 days based on uric acid response, and is absolutely contraindicated in patients with G6PD deficiency. 1, 2

Dosing Recommendations

FDA-Approved Dosing

The FDA-approved regimen is 0.15-0.2 mg/kg once daily for up to 5 days 2. However, this represents the upper end of effective dosing based on subsequent evidence.

Evidence-Based Practical Dosing

For Adults:

• Fixed dose of 6 mg as a single dose is sufficient for most adults with TLS, balancing efficacy and cost 3, 4
• Consider 3-4.5 mg single dose if baseline uric acid <12 mg/dL 3
• Weight-based dosing of 0.10-0.2 mg/kg daily remains an alternative 1
• Duration: 1-7 days (average 3 days), guided by uric acid levels 1

For Pediatric Patients:

• 1.5 mg or 0.15 mg/kg as a single dose is typically sufficient 3
• Children <2 years may require closer monitoring as they have higher uric acid AUC and lower rates of normalization by 48 hours (83% vs 93%) 2

Dosing Flexibility

• In massive tumor lysis, increase to twice daily administration 1
• Stop treatment when uric acid is extremely low or undetectable 1
• Monitor uric acid levels regularly to guide dose adjustments 1

Administration

• Dilute in 50 mL normal saline 1
• Infuse over 30 minutes 1, 2
• Never administer as IV bolus 2
• Indicated only for single course of treatment 2

Absolute Contraindications

Rasburicase is absolutely contraindicated in:

1. G6PD deficiency - causes life-threatening hemolysis and methemoglobinemia 1, 2, 5
2. Pregnancy and lactation 1, 2
3. History of:
   • Anaphylaxis to rasburicase 2
   • Severe hypersensitivity reactions 2
   • Hemolysis from rasburicase 2
   • Methemoglobinemia from rasburicase 2

G6PD Screening - Critical Safety Step

Before administering rasburicase, screen for G6PD deficiency through:

• Thorough history: Prior drug-induced hemolytic anemia 1
• Ethnic background assessment: Higher risk in African American, Mediterranean, and Southeast Asian descent 1, 5
• Quantitative enzyme assay remains the mainstay of screening 5
• Definitive testing: RBC NADPH formation measurement 1

Important Caveat

Enzymatic testing may be unreliable in hyperleukocytosis or recent transfusions 6. In these cases, consider genetic testing via whole exome sequencing for definitive G6PD variant classification 6. If G6PD status is unknown in high-risk ethnic groups, exercise extreme caution and consider alternative agents 7, 6.

Monitoring Parameters

Uric Acid Monitoring - Special Handling Required

Critical: Rasburicase degrades uric acid ex vivo at room temperature, causing falsely low readings 1, 2

Proper sample collection:

• Collect blood in pre-chilled heparin tubes 1, 2
• Immediately immerse in ice water bath 1, 2
• Centrifuge in pre-cooled centrifuge (4°C) 2
• Analyze within 4 hours of collection 1, 2

Clinical Monitoring

• Uric acid levels: Monitor regularly to guide dosing decisions 1
• Hemolysis parameters: Watch for signs of hemolytic anemia (pallor, jaundice, dark urine, elevated LDH, decreased haptoglobin) 8, 9
• Methemoglobin levels: If cyanosis or hypoxia develops 8
• Renal function: Creatinine, urine output
• Electrolytes: Particularly potassium and phosphate

Serious Adverse Reactions

Immediately and permanently discontinue rasburicase if:

• Anaphylaxis or severe hypersensitivity reaction occurs 2
• Hemolysis develops 2
• Methemoglobinemia occurs 2

Other serious reactions (rare):

• Rash, fever, neutropenia, respiratory distress, sepsis, mucositis 1

Common adverse reactions (≥20%):

• Vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, elevated ALT 2

Management of Rasburicase-Induced Complications

For hemolysis or methemoglobinemia:

• Immediately discontinue rasburicase 8, 7
• Methylene blue for methemoglobinemia (BUT contraindicated if G6PD deficiency confirmed) 8
• Ascorbic acid as alternative treatment 8, 7, 6
• Blood transfusion with low threshold for acute hemolytic anemia 8, 6
• Supportive oxygen therapy 8

Special Populations

• Asthma/atopic allergy: Limited experience; use with caution 1
• Geriatric patients: No dose adjustment needed; similar pharmacokinetics to younger adults 2
• Renal insufficiency: No dose adjustment required (unlike allopurinol) 1

Clinical Pearls

• Antibody formation occurs in 10% of patients 1
• After initial rasburicase, subsequent allopurinol is not necessary per expert opinion 1
• Rasburicase is preferred over allopurinol for preexisting hyperuricemia ≥7.5 mg/dL 1
• No metabolic drug interactions with common chemotherapy agents (allopurinol, cytarabine, methotrexate, 6-mercaptopurine, cyclophosphamide, vincristine) 2